Taper Or Abrupt Steroid Stop: TOASSTtrial

Phase 4 Recruiting 530 enrolled University Hospital, Basel, Switzerland Gebauer Stiftung Zurich · collab HEMMI Stiftung Switzerland · collab Kantonsspital Baselland Bruderholz · collab Swiss National Science Foundation · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is an Investigator-initiated, placebo-controlled, multicenter noninferiority trial, comparing rapid termination of systemic glucocorticoid treatment with a tapering regime over 4 weeks.

Timeline

Start: 2017-05-31
Primary completion: 2027-06
Completion: 2027-06

Publications

Komminoth M, Donath MY, Hepprich M, Schuetz P, Blum CA, Mueller B, Reny JL, Gosselin P, Breville G, Brandle M, Henzen C, Leuppi JD, Kistler AD, Thurnheer R, Beuschlein F, Rudofsky G, Aeberli D, Villiger PM, Bohm S, Chifu I, Fassnacht M, Meyer G, Bojunga J, Cattaneo M, Sluka C, Schneider H, Rutishauser J; <<TOASST>> study group. Glucocorticoid withdrawal and glucocorticoid-induced adrenal insufficiency: Study protocol of the randomized controlled <<TOASST" (Taper Or Abrupt Steroid STop) multicenter trial. PLoS One. 2023 Apr 5;18(4):e0281585. doi: 10.1371/journal.pone.0281585. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Prednisone	Other / unclassified	2.5 mg	—

Taper Or Abrupt Steroid Stop: TOASSTtrial

Summary

Timeline

Publications

Drugs

Indications